Investors

2017 News

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
May 03, 2017CTI BioPharma Reports First Quarter 2017 Financial Results
- Pacritinib Marketing Authorization Application Submission Expected Mid-Year - Expanded Partnership with Servier for Commercialization of PIXUVRI® - Management to Host Conference Call/ Webcast Today at 4:30 p.m. Eastern time SEATTLE, May 3, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the first quarter ended March 31, 2017. Recent Highlights In April 2017, CTI BioPharma announced the expansion of the existing license and ... 
Printer Friendly Version
Apr 26, 2017CTI BioPharma to Report First Quarter 2017 Financial Results on May 3, 2017
SEATTLE, April 26, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management plans to report its first quarter 2017 financial results on Wednesday, May 3, 2017, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows: ... 
Printer Friendly Version
Apr 25, 2017Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®
- Servier will commercialize PIXUVRI in all markets except the US - CTI BioPharma will retain rights to commercialize PIXUVRI in the US PARIS and SEATTLE, April 25, 2017 /PRNewswire/ -- Servier and CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today jointly announced that they agreed to expand their existing license and development collaboration agreement for PIXUVRI® (pixantrone). Under this expanded agreement, Servier will have rights to PIXUVRI in all markets except the U... 
Printer Friendly Version
Mar 08, 2017CTI BioPharma to Present at the 29th Annual ROTH Conference
SEATTLE, March 8, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 3:30 p.m. PT/6:30 p.m. ET in Dana Point, CA. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com. About CTI BioPharma CTI BioPharma Corp. is a biopharmaceutica... 
Printer Friendly Version
Mar 02, 2017CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results
SEATTLE, March 2, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2016. "The presentation of detailed results from the Phase 3 PERSIST-2 trial of pacritinib at the ASH Annual Meeting in December demonstrated that pacritinib may have potential to address a critical unmet need for myelofibrosis patients with low blood platelets or those ineligible to receive, intolerant of or which have insu... 
Printer Friendly Version
Feb 27, 2017CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO
SEATTLE, Feb. 27, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced the appointment of Adam Craig, M.D., Ph.D., as President and Chief Executive Officer (CEO) and member of the Board of Directors effective March 20, 2017. Dr. Craig succeeds Richard Love, interim President and CEO who will continue to serve on the company's Board of Directors.  Dr. Craig has over 20 years of experience in hematology, oncology and drug development in both the US and Eu... 
Printer Friendly Version
Feb 23, 2017CTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
SEATTLE, Feb. 23, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management plans to report its fourth quarter and full year 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtaine... 
Printer Friendly Version
Feb 08, 2017CTI BioPharma to Present at the BIO CEO & Investor Conference
SEATTLE, Feb. 8, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the the BIO CEO & Investor Conference on Tuesday, February 14, 2017, at 8:00 a.m. ET/2:00 p.m. CET in New York. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com. About CTI BioPharma CTI BioPharma Corp. is a biopharmaceutical company focused on the ac... 
Printer Friendly Version
Jan 24, 2017CTI Biopharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors
SEATTLE, Jan. 24, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Michael A. Metzger has been appointed a Director of CTI BioPharma. Mr. Metzger brings extensive experience leading and growing companies in the biopharmaceutical industry over the last 20 years. "We are pleased to welcome Michael to the Board of CTI BioPharma," said Richard Love, Interim President and CEO of CTI BioPharma. "Michael is an accomplished leader and builder of bio... 
Printer Friendly Version
Jan 09, 2017CTI BioPharma Announces Progress Of Lead Programs And Strategic Objectives For 2017
SEATTLE, Jan. 9, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced positive progress on its lead programs in addition to key business priorities for 2017. "Throughout 2016 we maintained our commitment to bringing new therapies to patients with unmet medical needs, and were successful in working with the FDA to remove the full clinical hold on pacritinib and get it back on the development track for the benefit of myelofibrosis patients," said Richa... 
Printer Friendly Version
Jan 05, 2017CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib
SEATTLE, Jan. 5, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted under the Investigational New Drug (IND) application for pacritinib has now been removed. The Company's complete response submission included, among other items, final Clinical Study Reports for both PERSIST-1 and 2 trials and a dose-exploration clini... 
Printer Friendly Version